File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan

TitleVildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan
Authors
Issue Date2009
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IJCP
Citation
International Journal Of Clinical Practice, 2009, v. 63 n. 10, p. 1446-1450 How to Cite?
AbstractSummaryAims: To compare hypoglycaemic events, glycated haemoglobin (HbA1c) and changes in bodyweight in metformin-treated Muslim patients with type 2 diabetes receiving adjunctive treatment with vildagliptin or gliclazide during Ramadan fasting. Methods: Data were collected from Muslim patients with type 2 diabetes attending primary care practices in North West London, whose HbA1c was > 8.5% despite treatment with metformin 2 g daily before Ramadan and who received gliclazide 160 mg twice daily (n = 26) or vildagliptin 50 mg twice daily (n = 26) in addition to metformin. Hypoglycaemic events, HbA1c and weight were recorded 2 weeks before and 10 days after the Ramadan fast. All patients received education about how to identify and manage hypoglycaemia during Ramadan. Results: During Ramadan, at least one hypoglycaemic event (defined as blood glucose < 3.5 mmol/l with or without symptoms) was recorded in two patients receiving vildagliptin (7.7%) and 16 patients receiving gliclazide [61.5%; difference between groups -53.8%, 95% confidence interval (CI) -74.9 to -26.3, p < 0.001]. Vildagliptin was associated with a reduction in the mean number of hypoglycaemic events during Ramadan compared with before Ramadan, whereas gliclazide was associated with an increase (least squares mean difference between groups -0.66, 95% CI -1.20 to -0.13, p = 0.0168). Both gliclazide and vildagliptin were associated with similar reductions in HbA1c and a small, but insignificant, increase in weight. Conclusions: Appropriate treatment adjustments can lead to improved diabetes management during Ramadan, with avoidance of significant weight gain and improved glucose control without hypoglycaemia. The addition of vildagliptin to metformin therapy during Ramadan in Muslim patients with type 2 diabetes was associated with a reduction in the incidence of hypoglycaemia. © 2009 Blackwell Publishing Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/167066
ISSN
2015 Impact Factor: 2.226
2015 SCImago Journal Rankings: 0.759
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorDevendra, Den_US
dc.contributor.authorGohel, Ben_US
dc.contributor.authorBravis, Ven_US
dc.contributor.authorHui, Een_US
dc.contributor.authorSalih, Sen_US
dc.contributor.authorMehar, Sen_US
dc.contributor.authorHassanein, Men_US
dc.date.accessioned2012-09-28T04:02:40Z-
dc.date.available2012-09-28T04:02:40Z-
dc.date.issued2009en_US
dc.identifier.citationInternational Journal Of Clinical Practice, 2009, v. 63 n. 10, p. 1446-1450en_US
dc.identifier.issn1368-5031en_US
dc.identifier.urihttp://hdl.handle.net/10722/167066-
dc.description.abstractSummaryAims: To compare hypoglycaemic events, glycated haemoglobin (HbA1c) and changes in bodyweight in metformin-treated Muslim patients with type 2 diabetes receiving adjunctive treatment with vildagliptin or gliclazide during Ramadan fasting. Methods: Data were collected from Muslim patients with type 2 diabetes attending primary care practices in North West London, whose HbA1c was > 8.5% despite treatment with metformin 2 g daily before Ramadan and who received gliclazide 160 mg twice daily (n = 26) or vildagliptin 50 mg twice daily (n = 26) in addition to metformin. Hypoglycaemic events, HbA1c and weight were recorded 2 weeks before and 10 days after the Ramadan fast. All patients received education about how to identify and manage hypoglycaemia during Ramadan. Results: During Ramadan, at least one hypoglycaemic event (defined as blood glucose < 3.5 mmol/l with or without symptoms) was recorded in two patients receiving vildagliptin (7.7%) and 16 patients receiving gliclazide [61.5%; difference between groups -53.8%, 95% confidence interval (CI) -74.9 to -26.3, p < 0.001]. Vildagliptin was associated with a reduction in the mean number of hypoglycaemic events during Ramadan compared with before Ramadan, whereas gliclazide was associated with an increase (least squares mean difference between groups -0.66, 95% CI -1.20 to -0.13, p = 0.0168). Both gliclazide and vildagliptin were associated with similar reductions in HbA1c and a small, but insignificant, increase in weight. Conclusions: Appropriate treatment adjustments can lead to improved diabetes management during Ramadan, with avoidance of significant weight gain and improved glucose control without hypoglycaemia. The addition of vildagliptin to metformin therapy during Ramadan in Muslim patients with type 2 diabetes was associated with a reduction in the incidence of hypoglycaemia. © 2009 Blackwell Publishing Ltd.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IJCPen_US
dc.relation.ispartofInternational Journal of Clinical Practiceen_US
dc.subject.meshAdamantane - Administration & Dosage - Analogs & Derivativesen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshBlood Glucose - Metabolismen_US
dc.subject.meshDiabetes Mellitus, Type 2 - Drug Therapy - Ethnologyen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFasting - Blooden_US
dc.subject.meshFemaleen_US
dc.subject.meshGliclazide - Administration & Dosageen_US
dc.subject.meshHemoglobin A, Glycosylated - Metabolismen_US
dc.subject.meshHumansen_US
dc.subject.meshHypoglycemia - Etiology - Prevention & Controlen_US
dc.subject.meshHypoglycemic Agents - Administration & Dosageen_US
dc.subject.meshIslamen_US
dc.subject.meshMaleen_US
dc.subject.meshMetformin - Administration & Dosageen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNitriles - Administration & Dosageen_US
dc.subject.meshPyrrolidines - Administration & Dosageen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleVildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadanen_US
dc.typeArticleen_US
dc.identifier.emailHui, E: eylhui@hku.hken_US
dc.identifier.authorityHui, E=rp01660en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1742-1241.2009.02171.xen_US
dc.identifier.pmid19678856-
dc.identifier.scopuseid_2-s2.0-70349245219en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70349245219&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume63en_US
dc.identifier.issue10en_US
dc.identifier.spage1446en_US
dc.identifier.epage1450en_US
dc.identifier.isiWOS:000269805800010-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridDevendra, D=6701796681en_US
dc.identifier.scopusauthoridGohel, B=36663680200en_US
dc.identifier.scopusauthoridBravis, V=25651274000en_US
dc.identifier.scopusauthoridHui, E=25651582800en_US
dc.identifier.scopusauthoridSalih, S=35263298800en_US
dc.identifier.scopusauthoridMehar, S=35262530100en_US
dc.identifier.scopusauthoridHassanein, M=7004441683en_US
dc.identifier.citeulike5808007-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats